Phase 2 N=463 A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Ovarian Neoplasms · Ovarian Cancer
Primary: Objective Response Rate (ORR) — 27.66 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=124 Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)
Chronic Hepatitis B
Primary: Percentage of Participants Achieving Virologic Response (Plasma Hepatitis B Virus [HBV] Deoxyribonucleic Acid [DNA] < 20 IU/mL) at Week 24 — 97.4; 100.0; 100.0…
Phase 2 N=38 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Carcinoma of the Collecting Ducts of Bellini · Chromophobe Renal Cell Carcinoma · Kidney Medullary Carcinoma
Primary: Overall Survival Rate at 12 Months — 65.7 percentage of participants
Phase 2 N=11 Oxytocin and Affect Processing in Posttraumatic Stress Disorder
Posttraumatic Stress Disorder (PTSD)
Primary: fMRI Analysis: Change in Anterior Insula Region — -12.6; -1.6; 10.6; -7.8 percentage of area activation
Phase 2 N=48 Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)
Pneumonia Due to Staphylococcus Aureus
Primary: Efficacy Endpoint: All-Cause Mortality by Day 28 — 1; 2; 2; 0 Participants
Phase 2 N=47 Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 — -4.5; -8.7; -5.5 score on a scale — p=0.7500
Phase 2 N=20 Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
Alopecia
Primary: Change in Hair Count — 7.7; 22.7 percent change — p=.009
Phase 2 N=27 IVIG-eye Drops Treatment for Dry Eye Disease
Dry Eye
Primary: Tolerability: The Primary Tolerability Endpoint is the Test Substance Tolerance (Visual Analog Scale) at 8 Weeks (56 Days) — 100; 100 score on a scale — p=1.000
Phase 2 N=15 Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study
Chemotherapy-induced Nausea and Vomiting
Primary: Patient Outcomes — 15; 15; 0 Participants
Phase 2 N=60 Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Stem Cell Transplantation · Leukemia · Lymphoma
Primary: Number of Participants With Survival Rate at 100 Days Post-transplant — 45 Participants
Phase 2 N=174 Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)
Duchenne Muscular Dystrophy · Becker Muscular Dystrophy
Primary: Change From Baseline in 6MWD at Week 48 — -41.81; -12.86; -42.56 meters — p=0.4756
Phase 2 N=90 A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Sarcoma
Primary: Average Number of Months of Progression-free Survival — 4.1; 4.1 months
Phase 2 N=46 Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Immune Response to Sipuleucel-T — 29.6; 25.45 Spots per ml
Phase 2 N=59 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Month 2 — 2.783; -27.478 percent change — p=<0.001
Phase 2 N=140 Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Neuroblastoma
Primary: Number of Participants With Event Free Survival (EFS) During Study. — 84; 51 percentage of subjects without an event